Key Highlights

  • Johnson & Johnson (NYSE:JNJ) said on November 10, 2026 that Caplyta met the primary and key secondary endpoints in Study 452, a second Phase 3 trial in adults with manic episodes of bipolar I disorder.
  • At week three, once-daily 42 mg Caplyta improved the Young Mania Rating Scale score by 3.7 points more than placebo, with benefit seen from day three.
  • Clinical response, defined as at least a 50% improvement, was 43.9% with Caplyta against 23.7% with placebo.
  • The company plans a US submission supported by Studies 451 and 452; Caplyta is not yet approved for bipolar mania.

What the Trial Showed

Study 452 enrolled adults with bipolar I disorder experiencing manic episodes, with or without mixed features, and compared a 42 mg daily dose of Caplyta with placebo over three weeks. The drug met its primary endpoint, the change in the Young Mania Rating Scale, with a 3.7 point advantage over placebo that was highly statistically significant. Improvement appeared by day three and held through the end of the study, which matters in acute mania, where rapid control of symptoms is the clinical priority. The response rate nearly doubled against placebo, at 43.9% versus 23.7%. Dizziness, dry mouth and somnolence or sedation were the side effects seen in at least 5% of treated patients and at least twice as often as on placebo. With Study 451 already in hand, Johnson & Johnson (NYSE:JNJ) now has the two positive pivotal trials normally needed for a new indication. That gives regulators a consistent body of evidence across separate patient populations, which typically supports a smoother review.

Why It Matters for the Neuroscience Franchise

Caplyta came to the company through its 2025 Acquisition of Intra-Cellular Therapies, and it is already approved for bipolar I and II depression and for major depressive disorder as an add-on or stand-alone therapy, as well as for schizophrenia. Adding mania would let the drug cover both poles of bipolar I disorder, a selling point for psychiatrists who prefer to keep patients on one medicine across mood states. Caplyta has built its position on a tolerability profile with relatively low rates of weight gain and movement side effects compared with older antipsychotics, a key Factor in long-term adherence. A broader label also extends the commercial life of the asset as the company leans on neuroscience to offset pressure from Biosimilars on its older immunology drugs. Each new indication gives the sales force a fresh reason to engage prescribers and supports the case that the acquisition price was justified. Management has highlighted neuroscience as one of the fastest-growing parts of its pharmaceutical business.

What Comes Next

The next step is a filing with US regulators, followed by a standard review that would put any approval decision most likely in 2027. Acute mania is a crowded field with several established antipsychotics, many available as generics, so pricing and payer access will shape how much new Revenue the indication brings. Physicians will also compare the size of the effect with existing options. For Johnson & Johnson (NYSE:JNJ), a single label expansion is modest against total group sales, but steady growth in neuroscience supports the broader pharmaceutical outlook. Investors should watch the timing of the submission, full data at a medical meeting and Caplyta sales trends in coming quarterly results. Any update on long-term maintenance data in bipolar disorder would also strengthen the case for using the drug across the full course of the illness.

Where Things Stand

Caplyta has now produced two positive Phase 3 trials in bipolar mania, with Study 452 showing a 3.7 point advantage on the mania scale and a 43.9% response rate. Johnson & Johnson plans a US filing for the indication. Approval would let the drug cover both mania and depression in bipolar I disorder, strengthening a neuroscience Franchise that the company is relying on for growth.